Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus

Therapeutics and Clinical Risk Management

Volumn 8, Issue , 2012, Pages 76-86

  Hagihara, Mao ^a   Umemura, Takumi ^a   Mori, Takeshi ^a,b   Mikamo, Hiroshige ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MEIJO UNIVERSITY   (Japan)

Author keywords

Daptomycin; Japan; Methicillin resistant staphylococcus aureus (MRSA)

Indexed keywords

DAPTOMYCIN; GENTAMICIN; HABEKACIN; LINEZOLID; RIFAMPICIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BONE MARROW SUPPRESSION; DIARRHEA; DISTRIBUTION VOLUME; DRUG APPROVAL; DRUG EFFICACY; DRUG EXCRETION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; EOSINOPHIL; HUMAN; JAPAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MYOPATHY; NECROTIZING FASCIITIS; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PATIENT SATISFACTION; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; THROMBOCYTE; THROMBOCYTOPENIA;

EID: 84870461453     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S23875     Document Type: Review

References (59)

1. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis. 2007;13:1840-1846.
2. Japan Nosocomial Infections Surveillance [homepage on the Internet]. Japan Nosocomial Infections Surveillance Report. Available from: http://www.nih-janis.jp/report/open_report/2010/2/1/ken_Open_ Report_201004.pdf. Accessed February 7, 2012. Japanese.
3. National Nosocomial Infections Surveillance. National Nosocomial Infections Surveillance system report, data summary from January 1992 through June 2004. Am Infect Control. 2004;32:470-485.
4. Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis. 2004;38:521-528.
5. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004;38:448-451.
6. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non- vancomycin- intermediate Staphylococcus aureus (VISA), vancomycinsusceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-2005. J Antimicrob Chemother. 2007;60:788-794.
7. Takesue Y, Nakajima K, Takahashi Y, et al. Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/mL methicillinresistant Staphylococcus aureus strains isolated from patients with bacteremia. J Infect Chemother. 2011;17:52-57.
8. Hagihara M, Wiskirchen DE, Kuti JL, Nicolau DP. In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2012;56:202-207.
9. Hatano K, Yokota Y, Hanaki H, Sunakawa K. Combined effect of vancomycin or teicoplanin plus a β-lactam antibiotic in mouse infection models caused by β-lactam antibiotic induced vancomycin-resistant MRSA (BIVR). Kansenshogaku Zasshi. 2006;80:243-250.
10. Hanaki H, Yamagushi Y. Epidemiological investigation of "β-lactam antibiotic induced vancomycin-resistant MRSA (BIVR)". Kansenshogaku Zasshi. 2003;77:499-504.
11. Saito N, Aoki K, Sakurai T, et al. Linezolid treatment for intracranial abscesses caused by methicillin-resistant Staphylococcus aureus - two case reports. Neurol Med Chir. 2010;50:515-517.
12. Endimiani A, Blackford M, Dasenbrook EC, et al. Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio. Antimicrob Agents Chemother. 2011;55:1684-1692.
13. Dumitrescu O, Boisset S, Badiou C, et al. Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin. Antimicrob Agents Chemother. 2007;5:1515-1519.
14. Dumitrescu O, Badiou C, Bes M, et al. Effect of antibiotics, alone and in combination, on Panton-Valentine leukocidin production by a Staphylococcus aureus reference strain. Clin Microbiol Infect. 2008;14:384-388.
15. Smith K, Gemmell CG, Hunter IS. The association between biocide tolerance and the presence or absence of qac genes among hospitalacquired and community-acquired MRSA isolates. J Antimicrob Chemother. 2008;61:78-84.
16. Yabe S, Takano T, Higuchi W, Mimura S, Kurosawa Y, Yamamoto T. Spread of the community-acquired methicillin-resistant Staphylococcus aureus USA300 clone among family members in Japan. J Infect Chemother. 2010;16:372-374.
17. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;17;355:666-674.
18. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother. 1990;34:1227-1231.
19. Bernareggi A, Borghi A, Borgonovi M, et al. Teicoplanin metabolism in humans. Antimicrob Agents Chemother. 1992;36: 1744-1749.
20. Hagihara M, Umemura T, Kimura M, Mori T, Hasegawa T, Mikamo H. Exploration of optimal teicoplanin dosage based on pharmacokinetic parameters for the treatment of intensive care unit patients infected with methicillin-resistant Staphylococcus aureus. J Infect Chemother. 2011. [Epub ahead of print.]
21. Kanazawa N, Matsumoto K, Ikawa K, Fukamizu T, Shigemi A, Yaji K. An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication. J Infect Chemother. 2011;17:297-300.
22. Cavalcanti AB, Goncalves AR, Almeida CS, Bugano DD, Silva E. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev. 2010;16:CD007022.
23. Matsumoto K, Takeshita A, Ikawa K, et al. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents. 2010;36:179-181.
24. Beibei L, Yun C, Mengli C, Nan B, Xuhong Y, Rui W. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. Int J Antimicrob Agents. 2010;35:3-12.
25. Tanigawara Y, Sato R, Morita K, Kaku M, Aikawa N, Shimizu K. Population pharmacokinetics of Arbekacin in patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50:3754-3762.
26. Oleson FB Jr, Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother. 2000;44:2948-2953.
27. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47: 2538-2544.
28. Alborn WE Jr, Allen NE, Preston DA. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother. 1991;35:2282-2287.
29. Hobbs JK, Miller K, O'Neill AJ, Chopra I. Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus. J Antimicrob Chemother. 2008;62:1003-1008.
30. King A, Phillips I. The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates. J Antimicrob Chemother. 2001;48:219-223.
31. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates. Antimicrob Agents Chemother. 2003;47:337-341.
32. Friedman L, Alder JD, Silverman JA. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50:2137-2145.
33. Julian K, Kosowska-Shick K, Whitener C, et al. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob Agents Chemother. 2007;51:3445-3448.
34. Muthaiyan A, Silverman JA, Jayaswal RK, et al. Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization. Antimicrob Agents Chemother. 2008;52:980-990.
35. Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50:1079-1082.
36. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC Jr, Eliopoulos GM. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother. 2006;50:1581-1585.
37. Patel JB, Jevitt LA, Hageman J, McDonald LC, Tenover FC. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis. 2006;42:1652-1653.
38. Eisenstein BI. Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Expert Opin Investig Drugs. 2004;13:1159-1169.
39. Oleson FB, Berman CL, Li AP. An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes. Chem Biol Interact. 2004;150:137-147.
40. Pertel PE, Bernardo P, Fogarty C, et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community- acquired pneumonia. Clin Infect Dis. 2008;46:1142-1151.
41. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005;191:2149-2152.
42. Cubicin® Summary of Product Characteristics. Available from: http://www.mrsa-cubicin.jp/secure/practitioner_download/index.html. Accessed February 7, 2012. Japanese.
43. Aikawa N, Kusachi S, Mikamo H, Takesue Y, Watanabe S, Toshinari T. Efficacy of daptomycin in Japanese patients with MRSA infection in relation to the susceptibility of baseline isolates in a randomized study. Poster A2-020. Chicago, IL: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology; 2011.
44. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. In: Approved Standards - Eighth Edition. CLSI document M07-A8. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.
45. Fowler VG Jr, Boucher HW, Corey GR, et al; S. aureus Endocarditis and Bactevenia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653-665.
46. Rand KH, Houck HJ. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2004;48:2871-2875.
47. Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004;48:63-68.
48. Cha R, Grucz RG Jr, Rybak MJ. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother. 2003;47:1598-1603.
49. Sakoulas G, Eliopoulos GM, Alder J, et al. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47:1714-1718.
50. John AK, Baldoni D, Haschke M, et al. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob Agents Chemother. 2009;53:2719-2724.
51. Tsuji BT, Rybak MJ. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2005;49:2735-2745.
52. Rehm SJ, Boucher H, Levine D, et al. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother. 2008;62:1413-1421.
53. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2004;48:4665-4672.
54. Hanberger H, Nilsson LE, Maller R, Isaksson B. Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob Agents Chemother. 1991;35:1710-1716.
55. Dvorchik B, Arbeit RD, Chung J, Liu S, Knebel W, Kastrissios H. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2004;48:2799-2807.
56. Cubist Pharmaceuticals Inc. Daptomycin: full prescribing information. Available from: http://www.cubicin.com/pdf/PrescribingInformation.pdf. Accessed February 10, 2012.
57. Odero RO, Cleveland KO, Gelfand MS. Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor. J Antimicrob Chemother. 2009;63:1299-1300.
58. Webster PS, Oleson FB Jr, Paterson DL, et al. Interaction of daptomycin with two recombinant thromboplastin reagents leads to falsely prolonged patient prothrombin time/International Normalized Ratio results. Blood Coagul Fibrinolysis. 2008;19:32-38.
59. Falagas ME, Rafailidis PI, Kasiakou SK, et al. Effectiveness and nephrotoxicity of colistin monotherapy vs colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin Microbiol Infect. 2006;12:1227-1230.